Safety in numbers: risankizumab for moderate-to-severe psoriasis

Br J Dermatol. 2022 Mar;186(3):394-395. doi: 10.1111/bjd.20947. Epub 2022 Feb 20.

Authors

S Mirali¹, K Fabusiwa², E Linos³

Affiliations

¹ University of Toronto Faculty of Medicine, Toronto, ON, Canada.
² Guy's and St Thomas' Hospital, London, UK.
³ Stanford University Department of Dermatology, Palo Alto, CA, USA.

PMID: 35187640
DOI: 10.1111/bjd.20947

No abstract available

Publication types

Comment

MeSH terms

Antibodies, Monoclonal* / adverse effects
Humans
Psoriasis* / drug therapy

Substances

Antibodies, Monoclonal
risankizumab